{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T10:17:32Z","timestamp":1778321852582,"version":"3.51.4"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s00406-017-0827-5","type":"journal-article","created":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T08:04:07Z","timestamp":1501574647000},"page":"191-208","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Use and safety of antiepileptic drugs in psychiatric inpatients\u2014data from the AMSP study"],"prefix":"10.1007","volume":"268","author":[{"given":"Katrin","family":"Druschky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Bleich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renate","family":"Grohmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolf R.","family":"Engel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Kleimann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"St\u00fcbner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waldemar","family":"Greil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sermin","family":"Toto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,8,1]]},"reference":[{"issue":"756\u2013762","key":"827_CR1","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1017\/s1092852900001504","volume":"6","author":"CW Bazil","year":"2001","unstructured":"Bazil CW (2001) Antiepileptic drugs in the 21st century. CNS Spectr 6(756\u2013762):765. doi: 10.1017\/s1092852900001504","journal-title":"CNS Spectr"},{"key":"827_CR2","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1055\/s-2007-996633","volume":"63","author":"J Walden","year":"1995","unstructured":"Walden J, He\u00dflinger B (1995) Bedeutung alter und neuer Antiepileptika in der Behandlung psychischer Erkrankungen (significance of old and new antiepileptic drugs in the treatment of psychiatric diseases). Fortschr Neurol Psychiatr 63:320\u2013335. doi: 10.1055\/s-2007-996633","journal-title":"Fortschr Neurol Psychiatr"},{"key":"827_CR3","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1001\/archneurpsyc.1943.02290150102005","volume":"49","author":"LB Kalinowsky","year":"1943","unstructured":"Kalinowsky LB, Putnam TJ (1943) Attempts at treatment of schizophrenia and other nonepileptic psychoses with dilantin. Arch Neurol Psychiatry 49:414\u2013420. doi: 10.1001\/archneurpsyc.1943.02290150102005","journal-title":"Arch Neurol Psychiatry"},{"key":"827_CR4","first-page":"25","volume":"1","author":"P Lambert","year":"1975","unstructured":"Lambert P, Carraz G, Borselli S, Bouchardy M (1975) Le dipropyl-acetamide dans le traitement de la psychose maniaco-depressive. L\u2019Encephale 1:25\u201331","journal-title":"L\u2019Encephale"},{"key":"827_CR5","first-page":"707","volume":"1","author":"PA Lambert","year":"1966","unstructured":"Lambert PA, Carraz G, Borselli S, Carbel S (1966) Action neuropsychotrope d\u2019un nouvel antiepileptique: le depamid. Ann Med Psychol 1:707\u2013710","journal-title":"Ann Med Psychol"},{"key":"827_CR6","first-page":"45","volume-title":"Anticonvulsants in affective disorders","author":"HM Emrich","year":"1984","unstructured":"Emrich HM, Dose M, von Zerssen D (1984) Action of sodium-valproate and of oxcarbazepine in patients with affective disorders. In: Emrich HM, \u014ckuma T, M\u00fcller AA (eds) Anticonvulsants in affective disorders. Excerpta Medica, Amsterdam, pp 45\u201355"},{"key":"827_CR7","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(62)91847-0","volume":"1","author":"S Blom","year":"1962","unstructured":"Blom S (1962) Trigeminal neuralgia: its treatment with a new anticonvulsant drug (G-32883). Lancet 1:839\u2013840. doi: 10.1016\/S0140-6736(62)91847-0","journal-title":"Lancet"},{"key":"827_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1055\/s-2007-1001167","volume":"58","author":"R Blank","year":"1990","unstructured":"Blank R (1990) Antikonvulsiva und ihre psychischen Wirkungen-eine \u00dcbersicht (Anticonvulsives and their psychic effects-a survey). Fortschr Neurol Psychiatr 58:19\u201332. doi: 10.1055\/s-2007-1001167","journal-title":"Fortschr Neurol Psychiatr"},{"key":"827_CR9","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/00002826-198509000-00003","volume":"8","author":"RW Evans","year":"1985","unstructured":"Evans RW, Gualtieri CT (1985) Carbamazepine: a neuropsychological and psychiatric profile. Clin Neuropharmacol 8:221\u2013241. doi: 10.1097\/00002826-198509000-00003","journal-title":"Clin Neuropharmacol"},{"key":"827_CR10","first-page":"1407","volume":"26","author":"H Krueger","year":"1964","unstructured":"Krueger H (1964) Klinischer Beitrag zur Therapie der Epilepsie mit einem Azepinderivat. Med Welt 26:1407\u20131413","journal-title":"Med Welt"},{"key":"827_CR11","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1055\/s-2003-39065","volume":"71","author":"DE Dietrich","year":"2003","unstructured":"Dietrich DE, Kropp S, Emrich HM (2003) Oxcarbazepin in der Behandlung affektiver und schizoaffektiver Erkrankungen (Oxcarbazepine in the treatment of affective and schizoaffective disorders). Fortschr Neurol Psychiatr 71:255\u2013264. doi: 10.1055\/s-2003-39065","journal-title":"Fortschr Neurol Psychiatr"},{"key":"827_CR12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3233\/ben-1990-31s104","volume":"3","author":"JW Faigle","year":"1990","unstructured":"Faigle JW, Menge GP (1990) Metabolic characteristics of oxcarbazepine (\u00aetrileptal) and their beneficial implications for enzyme induction and drug interactions. Behav Neurol 3:21\u201330. doi: 10.3233\/ben-1990-31s104","journal-title":"Behav Neurol"},{"key":"827_CR13","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/j.1528-1167.2007.00924.x","volume":"48","author":"AH Andreasen","year":"2007","unstructured":"Andreasen AH, Brosen K, Damkier P (2007) A comparative pharmacokinetic study in healthy volunteers of the effect of carbamazepine and oxcarbazepine on cyp3a4. Epilepsia 48:490\u2013496. doi: 10.1111\/j.1528-1167.2007.00924.x","journal-title":"Epilepsia"},{"key":"827_CR14","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1111\/j.1528-1157.1993.tb05921.x","volume":"34","author":"D Smith","year":"1993","unstructured":"Smith D, Chadwick D, Baker G, Davis G, Dewey M (1993) Seizure severity and the quality of life. Epilepsia 34:S31\u2013S35. doi: 10.1111\/j.1528-1157.1993.tb05921.x","journal-title":"Epilepsia"},{"key":"827_CR15","doi-asserted-by":"publisher","first-page":"79","DOI":"10.4088\/JCP.v60n0203","volume":"60","author":"JR Calabrese","year":"1999","unstructured":"Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD (1999) A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 study group. J Clin Psychiatry 60:79\u201388. doi: 10.4088\/JCP.v60n0203","journal-title":"J Clin Psychiatry"},{"key":"827_CR16","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S0165-1781(97)00082-6","volume":"72","author":"V Kusumakar","year":"1997","unstructured":"Kusumakar V, Yatham LN (1997) An open study of lamotrigine in refractory bipolar depression. Psychiatry Res 72:145\u2013148. doi: 10.1016\/S0165-1781(97)00082-6","journal-title":"Psychiatry Res"},{"key":"827_CR17","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.4088\/JCP.v64n0906","volume":"64","author":"JR Calabrese","year":"2003","unstructured":"Calabrese JR, Bowden CL, Sachs G, Yatham LN, Behnke K, Mehtonen OP, Montgomery P, Ascher J, Paska W, Earl N, DeVeaugh-Geiss J (2003) A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 64:1013\u20131024. doi: 10.4088\/JCP.v64n0906","journal-title":"J Clin Psychiatry"},{"key":"827_CR18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3109\/10401230009147081","volume":"12","author":"L Ichim","year":"2000","unstructured":"Ichim L, Berk M, Brook S (2000) Lamotrigine compared with lithium in mania: a double-blind randomized controlled trial. Ann Clin Psychiatry 12:5\u201310. doi: 10.3109\/10401230009147081","journal-title":"Ann Clin Psychiatry"},{"key":"827_CR19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/j.1600-0447.2005.00523.x","volume":"111","author":"DJ Muzina","year":"2005","unstructured":"Muzina DJ, Elhaj O, Gajwani P, Gao K, Calabrese JR (2005) Lamotrigine and antiepileptic drugs as mood stabilizers in bipolar disorder. Acta Psychiatr Scand 111:21\u201328. doi: 10.1111\/j.1600-0447.2005.00523.x","journal-title":"Acta Psychiatr Scand"},{"key":"827_CR20","doi-asserted-by":"publisher","first-page":"841","DOI":"10.4088\/JCP.v61n1106","volume":"61","author":"JR Calabrese","year":"2000","unstructured":"Calabrese JR, Suppes T, Bowden CL, Sachs GS, Swann AC, McElroy SL, Kusumakar V, Ascher JA, Earl NL, Greene PL, Monaghan ET (2000) A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 study group. J Clin Psychiatry 61:841\u2013850. doi: 10.4088\/JCP.v61n1106","journal-title":"J Clin Psychiatry"},{"key":"827_CR21","unstructured":"Fachinformation Pfizer Lyrica\u00ae Hartkapseln. Stand November 2016 Pfizer Pharma PFE GmbH, Berlin"},{"key":"827_CR22","doi-asserted-by":"crossref","first-page":"685","DOI":"10.2165\/00023210-200620080-00010","volume":"20","author":"JE Frampton","year":"2006","unstructured":"Frampton JE, Foster RH (2006) Pregabalin: in the treatment of generalised anxiety disorder. CNS Drugs 20:685\u2013693","journal-title":"CNS Drugs"},{"key":"827_CR23","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s40263-014-0192-0","volume":"28","author":"JE Frampton","year":"2014","unstructured":"Frampton JE (2014) Pregabalin: a review of its use in adults with generalized anxiety disorder. CNS Drugs 28:835\u2013854. doi: 10.1007\/s40263-014-0192-0","journal-title":"CNS Drugs"},{"key":"827_CR24","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1055\/s-2004-815505","volume":"37","author":"R Grohmann","year":"2004","unstructured":"Grohmann R, Engel RR, Ruther E, Hippius H (2004) The AMSP drug safety program: methods and global results. Pharmacopsychiatry 37:S4\u2013S11. doi: 10.1055\/s-2004-815505","journal-title":"Pharmacopsychiatry"},{"key":"827_CR25","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00406-013-0419-y","volume":"264","author":"R Grohmann","year":"2014","unstructured":"Grohmann R, Engel RR, Moller HJ, Ruther E, van der Velden JW, Stubner S (2014) Flupentixol use and adverse reactions in comparison with other common first- and second-generation antipsychotics: data from the AMSP study. Eur Arch Psychiatry Clin Neurosci 264:131\u2013141. doi: 10.1007\/s00406-013-0419-y","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"827_CR26","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","volume":"26","author":"CJ Clopper","year":"1934","unstructured":"Clopper CJ, Pearson ES (1934) The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 26:404\u2013413. doi: 10.1093\/biomet\/26.4.404","journal-title":"Biometrika"},{"key":"827_CR27","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1002\/sim.4780120902","volume":"12","author":"SE Vollset","year":"1993","unstructured":"Vollset SE (1993) Confidence intervals for a binomial proportion. Stat Med 12:809\u2013824. doi: 10.1002\/sim.4780120902","journal-title":"Stat Med"},{"key":"827_CR28","first-page":"53","volume-title":"Seizures, affective disorders and anticonvulsant drugs","author":"RM Post","year":"2002","unstructured":"Post RM, Speer AM (2002) A brief history of anticonvulsant use in affective disorders. In: Trimble MR, Schmitz B (eds) Seizures, affective disorders and anticonvulsant drugs. Clarius Press, Surrey, pp 53\u201381"},{"key":"827_CR29","first-page":"215","volume":"21","author":"RT Dunn","year":"1998","unstructured":"Dunn RT, Frye MS, Kimbrell TA, Denicoff KD, Leverich GS, Post RM (1998) The efficacy and use of anticonvulsants in mood disorders. Clin Neuropharmacol 21:215\u2013235","journal-title":"Clin Neuropharmacol"},{"key":"827_CR30","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2165\/00023210-200721010-00005","volume":"21","author":"RM Post","year":"2007","unstructured":"Post RM, Ketter TA, Uhde T, Ballenger JC (2007) Thirty years of clinical experience with carbamazepine in the treatment of bipolar illness: principles and practice. CNS Drugs 21:47\u201371. doi: 10.2165\/00023210-200721010-00005","journal-title":"CNS Drugs"},{"key":"827_CR31","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1192\/bjp.bp.107.048504","volume":"194","author":"JR Geddes","year":"2009","unstructured":"Geddes JR, Calabrese JR, Goodwin GM (2009) Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry 194:4\u20139. doi: 10.1192\/bjp.bp.107.048504","journal-title":"Br J Psychiatry"},{"key":"827_CR32","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1192\/bjp.bp.110.084822","volume":"199","author":"LV Kessing","year":"2011","unstructured":"Kessing LV, Hellmund G, Geddes JR, Goodwin GM, Andersen PK (2011) Valproate v. lithium in the treatment of bipolar disorder in clinical practice: observational nationwide register-based cohort study. Br J Psychiatry 199:57\u201363. doi: 10.1192\/bjp.bp.110.084822","journal-title":"Br J Psychiatry"},{"key":"827_CR33","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1001\/archpsyc.60.4.392","volume":"60","author":"CL Bowden","year":"2003","unstructured":"Bowden CL, Calabrese JR, Sachs G, Yatham LN, Asghar SA, Hompland M, Montgomery P, Earl N, Smoot TM, DeVeaugh-Geiss J (2003) A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 60:392\u2013400. doi: 10.1001\/archpsyc.60.4.392","journal-title":"Arch Gen Psychiatry"},{"key":"827_CR34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1176\/appi.ajp.159.1.1","volume":"159","author":"American Psychiatric Association","year":"2002","unstructured":"American Psychiatric Association (2002) Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 159:1\u201350","journal-title":"Am J Psychiatry"},{"key":"827_CR35","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1176\/appi.ajp.163.1.159-a","volume":"163","author":"S Raskin","year":"2006","unstructured":"Raskin S, Teitelbaum A, Zislin J, Durst R (2006) Adjunctive lamotrigine as a possible mania inducer in bipolar patients. Am J Psychiatry 163:159\u2013160. doi: 10.1176\/appi.ajp.163.1.159-a","journal-title":"Am J Psychiatry"},{"key":"827_CR36","first-page":"195","volume":"41","author":"S Selek","year":"2007","unstructured":"Selek S, Savas HA (2007) Lamotrigine-induced manic switches have already been reported. Aust N Z J Psychiatry 41:195","journal-title":"Aust N Z J Psychiatry"},{"key":"827_CR37","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1007\/s00115-014-4083-x","volume":"85","author":"T Bschor","year":"2014","unstructured":"Bschor T, M\u00fcller-Oerlinghausen B, Stoppe G, Hiemke C (2014) Neue Fakten zur Phasenprophylaxe der bipolar affektiven Erkrankung. Nervenarzt 85:1166\u20131170. doi: 10.1007\/s00115-014-4083-x","journal-title":"Nervenarzt"},{"key":"827_CR38","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/00004850-199004000-00002","volume":"5","author":"HM Emrich","year":"1990","unstructured":"Emrich HM (1990) Studies with oxcarbazepine (trileptal) in acute mania. Int Clin Psychopharmacol 5:83\u201388","journal-title":"Int Clin Psychopharmacol"},{"key":"827_CR39","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1586\/14737175.7.6.617","volume":"7","author":"E Popova","year":"2007","unstructured":"Popova E, Leighton C, Bernabarre A, Bernardo M, Vieta E (2007) Oxcarbazepine in the treatment of bipolar and schizoaffective disorders. Expert Rev Neurother 7:617\u2013626. doi: 10.1586\/14737175.7.6.617","journal-title":"Expert Rev Neurother"},{"key":"827_CR40","first-page":"208","volume-title":"Anticonvulsants in affective disorders, International Congress Series No. 626","author":"M Velikonja","year":"1984","unstructured":"Velikonja M, Heinrich K (1984) Effect of oxcarbazepine (CG 47.680) on affective and schizoaffective symptoms-a preliminary report. In: Emrich HM, Okuma T, Muller AA (eds) Anticonvulsants in affective disorders, International Congress Series No. 626. Excerpta Medica, Amsterdam, pp 208\u2013210"},{"key":"827_CR41","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1517\/13543784.8.7.1103","volume":"8","author":"SC Schachter","year":"1999","unstructured":"Schachter SC (1999) Oxcarbazepine: current status and clinical applications. Expert Opin Investig Drugs 8:1103\u20131112. doi: 10.1517\/13543784.8.7.1103","journal-title":"Expert Opin Investig Drugs"},{"key":"827_CR42","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1111\/j.1528-1157.1994.tb05967.x","volume":"35","author":"M Schmutz","year":"1994","unstructured":"Schmutz M, Brugger F, Gentsch C, McLean MJ, Olpe HR (1994) Oxcarbazepine: preclinical anticonvulsant profile and putative mechanisms of action. Epilepsia 35:S47\u2013S50. doi: 10.1111\/j.1528-1157.1994.tb05967.x","journal-title":"Epilepsia"},{"key":"827_CR43","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1080\/13651500310003336","volume":"8","author":"RG Lande","year":"2004","unstructured":"Lande RG (2004) Oxcarbazepine: efficacy, safety, and tolerability in the treatment of mania. Int J Psychiatry Clin Pract 8:37\u201340. doi: 10.1080\/13651500310003336","journal-title":"Int J Psychiatry Clin Pract"},{"key":"827_CR44","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0165-0327(88)90055-9","volume":"14","author":"M Maj","year":"1988","unstructured":"Maj M (1988) Lithium prophylaxis of schizoaffective disorders: a prospective study. J Affect Disord 14:129\u2013135","journal-title":"J Affect Disord"},{"key":"827_CR45","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/0364-7722(81)90035-7","volume":"5","author":"D Sarantidis","year":"1981","unstructured":"Sarantidis D, Waters B (1981) Predictors of lithium prophylaxis effectiveness. Prog Neuropsychopharmacol 5:507\u2013510. doi: 10.1016\/0364-7722(81)90035-7","journal-title":"Prog Neuropsychopharmacol"},{"key":"827_CR46","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1176\/ajp.156.8.1138","volume":"156","author":"DF Levinson","year":"1999","unstructured":"Levinson DF, Umapathy C, Musthaq M (1999) Treatment of schizoaffective disorder and schizophrenia with mood symptoms. Am J Psychiatry 156:1138\u20131148. doi: 10.1176\/ajp.156.8.1138","journal-title":"Am J Psychiatry"},{"key":"827_CR47","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1176\/ajp.153.5.711","volume":"153","author":"HH Fenn","year":"1996","unstructured":"Fenn HH, Robinson D, Luby V, Dangel C, Buxton E, Beattie M, Kraemer H, Yesavage JA (1996) Trends in pharmacotherapy of schizoaffective and bipolar affective disorders: a 5-year naturalistic study. Am J Psychiatry 153:711\u2013713. doi: 10.1176\/ajp.153.5.711","journal-title":"Am J Psychiatry"},{"key":"827_CR48","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1176\/appi.ps.53.1.94","volume":"53","author":"J Flynn","year":"2002","unstructured":"Flynn J, Grieger TA, Benedek DM (2002) Pharmacologic treatment of hospitalized patients with schizoaffective disorder. Psychiatr Serv 53:94\u201396. doi: 10.1176\/appi.ps.53.1.94","journal-title":"Psychiatr Serv"},{"key":"827_CR49","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/s0165-0327(02)00354-3","volume":"79","author":"C Baethge","year":"2004","unstructured":"Baethge C, Gruschka P, Berghofer A, Bauer M, Muller-Oerlinghausen B, Bschor T, Smolka MN (2004) Prophylaxis of schizoaffective disorder with lithium or carbamazepine: outcome after long-term follow-up. J Affect Disord 79:43\u201350. doi: 10.1016\/s0165-0327(02)00354-3","journal-title":"J Affect Disord"},{"key":"827_CR50","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1159\/000026527","volume":"38","author":"X Xie","year":"1998","unstructured":"Xie X, Hagan RM (1998) Cellular and molecular actions of lamotrigine: possible mechanisms of efficacy in bipolar disorder. Neuropsychobiology 38:119\u2013130. doi: 10.1159\/000026527","journal-title":"Neuropsychobiology"},{"key":"827_CR51","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S0920-1211(00)00196-0","volume":"43","author":"B Hassel","year":"2001","unstructured":"Hassel B, Tauboll E, Gjerstad L (2001) Chronic lamotrigine treatment increases rat hippocampal GABA shunt activity and elevates cerebral taurine levels. Epilepsy Res 43:153\u2013163. doi: 10.1016\/S0920-1211(00)00196-0","journal-title":"Epilepsy Res"},{"key":"827_CR52","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1185\/030079903125001703","volume":"19","author":"B Green","year":"2003","unstructured":"Green B (2003) Lamotrigine in mood disorders. Curr Med Res Opin 19:272\u2013277. doi: 10.1185\/030079903125001703","journal-title":"Curr Med Res Opin"},{"key":"827_CR53","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1176\/ajp.156.11.1833","volume":"156","author":"TM Maltese","year":"1999","unstructured":"Maltese TM (1999) Adjunctive lamotrigine treatment for major depression. Am J Psychiatry 156:1833. doi: 10.1176\/ajp.156.11.1833","journal-title":"Am J Psychiatry"},{"key":"827_CR54","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1159\/000026540","volume":"38","author":"A Erfurth","year":"1998","unstructured":"Erfurth A, Walden J, Grunze H (1998) Lamotrigine in the treatment of schizoaffective disorder. Neuropsychobiology 38:204\u2013205. doi: 10.1159\/000026540","journal-title":"Neuropsychobiology"},{"key":"827_CR55","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S0165-0327(99)00007-5","volume":"51","author":"OC Pinto","year":"1998","unstructured":"Pinto OC, Akiskal HS (1998) Lamotrigine as a promising approach to borderline personality: an open case series without concurrent DSM-IV major mood disorder. J Affect Disord 51:333\u2013343. doi: 10.1016\/S0165-0327(99)00007-5","journal-title":"J Affect Disord"},{"key":"827_CR56","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/0014-2999(95)00851-9","volume":"299","author":"I Lizasoain","year":"1996","unstructured":"Lizasoain I, Leza JC, Cuellar B, Moro MA, Lorenzo P (1996) Inhibition of morphine withdrawal by lamotrigine: involvement of nitric oxide. Eur J Pharmacol 299:41\u201345. doi: 10.1016\/0014-2999(95)00851-9","journal-title":"Eur J Pharmacol"},{"key":"827_CR57","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1055\/s-0028-1112128","volume":"42","author":"C Schonfeldt-Lecuona","year":"2009","unstructured":"Schonfeldt-Lecuona C, Wolf RC, Osterfeld ND, Vasic N, Connemann BJ, Schmid M, Freudenmann RW (2009) Pregabalin in the treatment of schizophrenic anxiety. Pharmacopsychiatry 42:124\u2013125. doi: 10.1055\/s-0028-1112128","journal-title":"Pharmacopsychiatry"},{"key":"827_CR58","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1097\/JCP.0b013e3181e5c095","volume":"30","author":"S Englisch","year":"2010","unstructured":"Englisch S, Esser A, Enning F, Hohmann S, Schanz H, Zink M (2010) Augmentation with pregabalin in schizophrenia. J Clin Psychopharmacol 30:437\u2013440. doi: 10.1097\/JCP.0b013e3181e5c095","journal-title":"J Clin Psychopharmacol"},{"key":"827_CR59","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1586\/14737175.7.7.769","volume":"7","author":"B Bandelow","year":"2007","unstructured":"Bandelow B, Wedekind D, Leon T (2007) Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention. Expert Rev Neurother 7:769\u2013781. doi: 10.1586\/14737175.7.7.769","journal-title":"Expert Rev Neurother"},{"key":"827_CR60","doi-asserted-by":"publisher","first-page":"CD004028","DOI":"10.1002\/14651858.CD004028.pub4","volume":"11","author":"Y Wang","year":"2016","unstructured":"Wang Y, Xia J, Helfer B, Li C, Leucht S (2016) Valproate for schizophrenia. Cochrane Database Syst Rev 11:CD004028. doi: 10.1002\/14651858.CD004028.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"827_CR61","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1358\/dot.2004.40.7.850478","volume":"40","author":"DF Zullino","year":"2004","unstructured":"Zullino DF, Khazaal Y, Hattenschwiler J, Borgeat F, Besson J (2004) Anticonvulsant drugs in the treatment of substance withdrawal. Drugs Today 40:603\u2013619. doi: 10.1358\/dot.2004.40.7.850478","journal-title":"Drugs Today"},{"key":"827_CR62","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1517\/13543784.14.4.371","volume":"14","author":"SW Book","year":"2005","unstructured":"Book SW, Myrick H (2005) Novel anticonvulsants in the treatment of alcoholism. Expert Opin Investig Drugs 14:371\u2013376. doi: 10.1517\/13543784.14.4.371","journal-title":"Expert Opin Investig Drugs"},{"key":"827_CR63","doi-asserted-by":"publisher","first-page":"12S","DOI":"10.1097\/00004714-199912002-00003","volume":"19","author":"K Rickels","year":"1999","unstructured":"Rickels K, DeMartinis N, Rynn M, Mandos L (1999) Pharmacologic strategies for discontinuing benzodiazepine treatment. J Clin Psychopharmacol 19:12S\u201316S. doi: 10.1097\/00004714-199912002-00003","journal-title":"J Clin Psychopharmacol"},{"key":"827_CR64","doi-asserted-by":"publisher","first-page":"6367","DOI":"10.2174\/13816128113199990425","volume":"19","author":"G Martinotti","year":"2013","unstructured":"Martinotti G, Lupi M, Sarchione F, Santacroce R, Salone A, De Berardis D, Serroni N, Cavuto M, Signorelli M, Aguglia E, Valchera A, Iasevoli F, Di Giannantonio M (2013) The potential of pregabalin in neurology, psychiatry and addiction: a qualitative overview. Curr Pharm Des 19:6367\u20136374. doi: 10.2174\/13816128113199990425","journal-title":"Curr Pharm Des"},{"key":"827_CR65","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0033-3182(86)72590-5","volume":"27","author":"S Lipper","year":"1986","unstructured":"Lipper S, Davidson JRT, Grady TA, Edinger JD, Hammett EB, Mahorney SL, Cavenar JO (1986) Preliminary study of carbamazepine in post-traumatic stress disorder. Psychosomatics 27:849\u2013854. doi: 10.1016\/S0033-3182(86)72590-5","journal-title":"Psychosomatics"},{"key":"827_CR66","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1176\/ajp.146.4.558b","volume":"146","author":"L Tondo","year":"1989","unstructured":"Tondo L, Burrai C, Scamonatti L, Toccafondi F, Poddighe A, Minnai G, Tundo A, Floris G (1989) Carbamazepine in panic disorder. Am J Psychiatry 146:558\u2013559. doi: 10.1176\/ajp.146.4.558b","journal-title":"Am J Psychiatry"},{"key":"827_CR67","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.psychres.2013.10.007","volume":"215","author":"C Anderson","year":"2014","unstructured":"Anderson C, George D, Quante A (2014) Pregabalin in acute treatment of anxious depression: a case series. Psychiatry Res 215:246\u2013248. doi: 10.1016\/j.psychres.2013.10.007","journal-title":"Psychiatry Res"},{"key":"827_CR68","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1177\/0269881107078496","volume":"21","author":"M Showraki","year":"2007","unstructured":"Showraki M (2007) Pregabalin in the treatment of depression. J Psychopharmacol 21:883\u2013884. doi: 10.1177\/0269881107078496","journal-title":"J Psychopharmacol"},{"key":"827_CR69","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/JCP.0b013e31827b9351","volume":"33","author":"M Vitali","year":"2013","unstructured":"Vitali M, Tedeschini E, Mistretta M, Fehling K, Aceti F, Ceccanti M, Fava M (2013) Adjunctive pregabalin in partial responders with major depressive disorder and residual anxiety. J Clin Psychopharmacol 33:95\u201398. doi: 10.1097\/JCP.0b013e31827b9351","journal-title":"J Clin Psychopharmacol"},{"key":"827_CR70","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1002\/gps.3800","volume":"28","author":"D Karaiskos","year":"2013","unstructured":"Karaiskos D, Pappa D, Tzavellas E, Siarkos K, Katirtzoglou E, Papadimitriou GN, Politis A (2013) Pregabalin augmentation of antidepressants in older patients with comorbid depression and generalized anxiety disorder\u2014an open-label study. Int J Geriatr Psychiatry 28:100\u2013105. doi: 10.1002\/gps.3800","journal-title":"Int J Geriatr Psychiatry"},{"key":"827_CR71","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.euroneuro.2008.01.004","volume":"18","author":"DJ Stein","year":"2008","unstructured":"Stein DJ, Baldwin DS, Baldinetti F, Mandel F (2008) Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: a pooled analysis of 6 studies. Eur Neuropsychopharmacol 18:422\u2013430. doi: 10.1016\/j.euroneuro.2008.01.004","journal-title":"Eur Neuropsychopharmacol"},{"key":"827_CR72","volume-title":"Handbuch bipolare st\u00f6rungen: grundlagen-diagnostik-therapie","author":"HJ Assion","year":"2006","unstructured":"Assion HJ, Angst J, Vollmoeller W (2006) Handbuch bipolare st\u00f6rungen: grundlagen-diagnostik-therapie. Kohlhammer, Stuttgart"},{"key":"827_CR73","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1177\/0269881115598411","volume":"29","author":"DS Baldwin","year":"2015","unstructured":"Baldwin DS, den Boer JA, Lyndon G, Emir B, Schweizer E, Haswell H (2015) Efficacy and safety of pregabalin in generalised anxiety disorder: a critical review of the literature. J Psychopharmacol 29:1047\u20131060. doi: 10.1177\/0269881115598411","journal-title":"J Psychopharmacol"},{"key":"827_CR74","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1093\/alcalc\/agr005","volume":"46","author":"F Eyer","year":"2011","unstructured":"Eyer F, Schreckenberg M, Hecht D, Adorjan K, Schuster T, Felgenhauer N, Pfab R, Strubel T, Zilker T (2011) Carbamazepine and valproate as adjuncts in the treatment of alcohol withdrawal syndrome: a retrospective cohort study. Alcohol Alcohol 46:177\u2013184. doi: 10.1093\/alcalc\/agr005","journal-title":"Alcohol Alcohol"},{"key":"827_CR75","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1080\/10550490190942489","volume":"10","author":"R Malcolm","year":"2001","unstructured":"Malcolm R, Myrick H, Brady KT, Ballenger JC (2001) Update on anticonvulsants for the treatment of alcohol withdrawal. Am J Addict 10:16\u201323. doi: 10.1080\/10550490190942489","journal-title":"Am J Addict"},{"key":"827_CR76","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1080\/10550490701375558","volume":"16","author":"G Martinotti","year":"2007","unstructured":"Martinotti G, Romanelli R, Di Nicola M, Reina D, Mazza M, Janiri L (2007) Oxcarbazepine at high dosages for the treatment of alcohol dependence. Am J Addict 16:247\u2013248. doi: 10.1080\/10550490701375558","journal-title":"Am J Addict"},{"key":"827_CR77","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1080\/13556210500224015","volume":"10","author":"G Schik","year":"2005","unstructured":"Schik G, Wedegaertner FR, Liersch J, Hoy L, Emrich HM, Schneider U (2005) Oxcarbazepine versus carbamazepine in the treatment of alcohol withdrawal. Addict Biol 10:283\u2013288. doi: 10.1080\/13556210500224015","journal-title":"Addict Biol"},{"key":"827_CR78","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/13556210071289","volume":"5","author":"U Schneider","year":"2000","unstructured":"Schneider U, Paetzold W, Eronat V, Huber TJ, Seifert J, Wiese B, Emrich HM (2000) Buprenorphine and carbamazepine as a treatment for detoxification of opiate addicts with multiple drug misuse: a pilot study. Addict Biol 5:65\u201369. doi: 10.1080\/13556210071289","journal-title":"Addict Biol"},{"key":"827_CR79","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3109\/13651501.2014.1000930","volume":"19","author":"KN Fountoulakis","year":"2015","unstructured":"Fountoulakis KN, Gonda X, Baghai T, Baldwin D, Bauer M, Blier P, Gattaz W, Hasler G, M\u00f6ller HJ, Tandon R, Vieta E, Kasper S (2015) Report of the WPA section of pharmacopsychiatry on the relationship of antiepileptic drugs with suicidality in epilepsy. Int J Psychiatry Clin Pract 19:158\u2013167","journal-title":"Int J Psychiatry Clin Pract"},{"key":"827_CR80","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.clineuro.2009.12.014","volume":"112","author":"K Zeng","year":"2010","unstructured":"Zeng K, Wang X, Xi Z, Yan Y (2010) Adverse effects of carbamazepine, phenytoin, valproate and lamotrigine monotherapy in epileptic adult Chinese patients. Clin Neurol Neurosurg 112:291\u2013295. doi: 10.1016\/j.clineuro.2009.12.014","journal-title":"Clin Neurol Neurosurg"},{"key":"827_CR81","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.eurpsy.2008.12.014","volume":"24","author":"AK Kakkar","year":"2009","unstructured":"Kakkar AK, Rehan HS, Unni KE, Gupta NK, Chopra D, Kataria D (2009) Comparative efficacy and safety of oxcarbazepine versus divalproex sodium in the treatment of acute mania: a pilot study. Eur Psychiatry 24:178\u2013182. doi: 10.1016\/j.eurpsy.2008.12.014","journal-title":"Eur Psychiatry"},{"key":"827_CR82","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.yebeh.2015.11.009","volume":"54","author":"AB Kowski","year":"2016","unstructured":"Kowski AB, Weissinger F, Gaus V, Fidzinski P, Losch F, Holtkamp M (2016) Specific adverse effects of antiepileptic drugs-a true-to-life monotherapy study. Epilepsy Behav 54:150\u2013157. doi: 10.1016\/j.yebeh.2015.11.009","journal-title":"Epilepsy Behav"},{"key":"827_CR83","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.jpain.2008.03.013","volume":"9","author":"LM Arnold","year":"2008","unstructured":"Arnold LM, Russell IJ, Diri EW, Duan WR, Young JP, Sharma U, Martin SA, Barrett JA, Haig G (2008) A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain 9:792\u2013805. doi: 10.1016\/j.jpain.2008.03.013","journal-title":"J Pain"},{"key":"827_CR84","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.3899\/jrheum.141196","volume":"42","author":"LM Arnold","year":"2015","unstructured":"Arnold LM, Sarzi-Puttini P, Arsenault P, Khan T, Brown PB, Clair A, Scavone JM, Driscoll J, Landen J, Pauer L (2015) Efficacy and safety of pregabalin in patients with fibromyalgia and comorbid depression taking concurrent antidepressant medication: a randomized, placebo-controlled study. J Rheumatol 42:1237\u20131244. doi: 10.3899\/jrheum.141196","journal-title":"J Rheumatol"},{"key":"827_CR85","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.pharep.2014.11.009","volume":"67","author":"B B\u0142aszczyk","year":"2015","unstructured":"B\u0142aszczyk B, Laso\u0144 W, Czuczwar SJ (2015) Antiepileptic drugs and adverse skin reactions: an update. Pharmacol Rep 67:426\u2013434. doi: 10.1016\/j.pharep.2014.11.009","journal-title":"Pharmacol Rep"},{"key":"827_CR86","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.4088\/JCP.08m04563","volume":"70","author":"C Lange-Asschenfeldt","year":"2009","unstructured":"Lange-Asschenfeldt C, Grohmann R, Lange-Asschenfeldt B, Engel RR, Ruther E, Cordes J (2009) Cutaneous adverse reactions to psychotropic drugs: data from a multicenter surveillance program. J Clin Psychiatry 70:1258\u20131265. doi: 10.4088\/JCP.08m04563","journal-title":"J Clin Psychiatry"},{"key":"827_CR87","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1111\/epi.13593","volume":"57","author":"S Gandhi","year":"2016","unstructured":"Gandhi S, McArthur E, Mamdani MM, Hackam DG, McLachlan RS, Weir MA, Burneo JG, Garg AX (2016) Antiepileptic drugs and hyponatremia in older adults: two population-based cohort studies. Epilepsia 57:2067\u20132079. doi: 10.1111\/epi.13593","journal-title":"Epilepsia"},{"key":"827_CR88","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/0920-1211(89)90070-3","volume":"3","author":"M Dam","year":"1989","unstructured":"Dam M, Ekberg R, Loyning Y, Waltimo O, Jakobsen K (1989) A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 3:70\u201376. doi: 10.1016\/0920-1211(89)90070-3","journal-title":"Epilepsy Res"},{"key":"827_CR89","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0920-1211(87)90025-8","volume":"1","author":"AC Johannessen","year":"1987","unstructured":"Johannessen AC, Nielsen OA (1987) Hyponatremia induced by oxcarbazepine. Epilepsy Res 1:155\u2013156. doi: 10.1016\/0920-1211(87)90025-8","journal-title":"Epilepsy Res"},{"key":"827_CR90","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1017\/s1461145711001192","volume":"15","author":"M Letmaier","year":"2012","unstructured":"Letmaier M, Painold A, Holl AK, Vergin H, Engel R, Konstantinidis A, Kasper S, Grohmann R (2012) Hyponatremia during psychopharmacological treatment: results of a drug surveillance programme. Int J Neuropsychopharmacol 15:739\u2013748. doi: 10.1017\/s1461145711001192","journal-title":"Int J Neuropsychopharmacol"},{"key":"827_CR91","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1345\/aph.1G209","volume":"39","author":"GM Kuz","year":"2005","unstructured":"Kuz GM, Manssourian A (2005) Carbamazepine-induced hyponatremia: assessment of risk factors. Ann Pharmacother 39:1943\u20131946. doi: 10.1345\/aph.1G209","journal-title":"Ann Pharmacother"},{"key":"827_CR92","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1002\/jmv.20676","volume":"78","author":"M-R Boulassel","year":"2006","unstructured":"Boulassel M-R, Morales R, Murphy T, Lalonde RG, Klein MB (2006) Gender and long-term metabolic toxicities from antiretroviral therapy in HIV-1 infected persons. J Med Virol 78:1158\u20131163. doi: 10.1002\/jmv.20676","journal-title":"J Med Virol"},{"key":"827_CR93","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2165\/00128071-200102060-00001","volume":"2","author":"M Rademaker","year":"2001","unstructured":"Rademaker M (2001) Do women have more adverse drug reactions? Am J Clin Dermatol 2:349\u2013351. doi: 10.2165\/00128071-200102060-00001","journal-title":"Am J Clin Dermatol"},{"key":"827_CR94","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ijnp\/pyv126","volume":"19","author":"M-E Friedrich","year":"2016","unstructured":"Friedrich M-E, Akimova E, Huf W, Konstandinidis A, Papageorgiou K, Winkler D, Toto S, Greil W, Grohmann R, Kasper S (2016) Drug-induced liver injury during antidepressant treatment: results of AMSP, a drug surveillance program. Int J Neuropsychopharmacol 19:1\u20139. doi: 10.1093\/ijnp\/pyv126","journal-title":"Int J Neuropsychopharmacol"},{"key":"827_CR95","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1055\/s-2004-815506","volume":"37","author":"R Engel","year":"2004","unstructured":"Engel R, Grohmann R, R\u00fcther E, Hippius H (2004) Research methods in drug surveillance. Pharmacopsychiatry 37:12\u201315. doi: 10.1055\/s-2004-815506","journal-title":"Pharmacopsychiatry"},{"key":"827_CR96","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/1471-244X-14-75","volume":"14","author":"MJ Clancy","year":"2014","unstructured":"Clancy MJ, Clarke MC, Connor DJ, Cannon M, Cotter DR (2014) The prevalence of psychosis in epilepsy; a systematic review and meta-analysis. BMC Psychiatry 14:75. doi: 10.1186\/1471-244X-14-75","journal-title":"BMC Psychiatry"}],"container-title":["European Archives of Psychiatry and Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00406-017-0827-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-017-0827-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-017-0827-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T21:58:18Z","timestamp":1569967098000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00406-017-0827-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,1]]},"references-count":96,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["827"],"URL":"https:\/\/doi.org\/10.1007\/s00406-017-0827-5","relation":{},"ISSN":["0940-1334","1433-8491"],"issn-type":[{"value":"0940-1334","type":"print"},{"value":"1433-8491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,1]]}}}